Men denied life-extending prostate cancer drug
A cancer charity has said it is "angry and frustrated" that ministers and health officials have not approved the provision of a life-extending prostate cancer drug through the NHS in England.
The drug, abiraterone, has been available in Scotland and Wales for two years for high-risk patients whose cancer has not yet spread, but not in England and Northern Ireland.
In a letter to Prostate Cancer UK, seen by the BBC, Health Minister Karin Smyth said the decision by NHS England, following a lengthy review, was "based on overall affordability" and that "it would not be appropriate to intervene".
The government said urgent advice had been requested on the issue.
The charity said it was a "dire and urgent situation in England" with "a bureaucratic blockage denying men this treatment".
A Department of Health and Social Care spokesperson said: "We understand the frustration and upset of some patients who cannot access this potentially life-saving treatment. Ministers have requested urgent advice on the issue."
Although not a cure, abiraterone can help stop prostate cancer spreading to other parts of the body.
In England and Northern Ireland, the drug is only approved for men with very advanced prostate cancer which has spread already.
In Wales and Scotland, people with the disease that has not yet spread can also get it.
Research has shown that for these earlier stage patients, the survival rate after six years is improved and that the drug halved the rate of progression of the cancer.
The charity says many lives could be extended by the drug, given the findings from a trial called Stampede, published in 2022.
It found improved odds of survival among men given the drug alongside usual care, and concluded that abiraterone should be considered a new standard treatment.
According to figures from NHS England, each year about 8,400 patients have high-risk prostate cancer that has not yet spread.
Using the Stampede assumptions, 672 of those men could die prematurely without access to abiraterone.
In October 2023, BBC News spoke to Giles Turner, a retired banker living in Sussex. He was diagnosed with prostate cancer earlier that year but was told that abiraterone could not be obtained on the NHS in England.
He chose to pay for treatment with the drug at £250 a month. He told us then that he felt "very fortunate" to be able to afford it, but outraged for others who could not.
At the time, NHS England said it was reviewing the drug's use for a wider range of men.
However, in December 2024 it told Prostate Cancer UK that "it has not been possible to identify the necessary recurrent headroom in revenue budgets".
Because abiraterone is a generic drug which has gone "off patent" and is licensed for only one group of prostate cancer patients, there is a complicated process to get it approved for wider use.
Each year, NHS England can make "discretionary" investment decisions with a specialist advisory group, but it has chosen not to for this drug.
Smyth's letter earlier this month said the process had to look at "the overall budget impact of introducing a new treatment based on patient volumes", and ministers would not intervene.
Mr Turner said he was "stunned" that nearly one-and-a-half years after the BBC report, NHS England had not caught up with NHS Scotland and NHS Wales.
He has spent £20,000 so far on his treatment, and said he felt it was wrong that while expensive new patented drugs treatments could be funded, abiraterone - costing the NHS £77 per pack per month - could not be.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Patients may be seen by any dental surgery
Patients could be moved around dental surgeries under proposed changes to the system. Instead of having a regular surgery, the changes could see people offered treatment at any practice within their health board area, with check-ups for those with healthy teeth pushed to every 18 to 24 months. The Welsh government said the proposals would improve access to dental services, particularly for those most in need. But the British Dental Association (BDA) said the opposite could happen and more patients may be forced to go private. The biggest change would see all patients over 18 placed onto a central waiting list, called the Dental Access Portal (DAP). They would then be allocated a surgery, which could be anywhere within the health board area. If they need treatment, they would remain with that surgery until it is complete and beyond, if they needed close monitoring. If or when teeth are healthy, patients would be returned to the central portal and would be recalled for a check-up in 18 to 24 months wherever there is space. Children would be assessed under the plans but stay at the first surgery they are allocated. Some charges for patients would also change - with check-ups going up from £20 to £24.75 but a single crown going down from £260 to £239.15. 'There could be no NHS dentists in two years' Welsh dentistry 'no example' to England Family unable to see a dentist in four years Health Minister Jeremy Miles said the plans would benefit everyone. "It will make NHS dentistry more attractive to dentists and that is good for patients," he said. "Actually, what we want to make sure is that patients do look after their own oral health but when they do need to see a dentist they will be able to access one which is the critical thing." Jody Pegler, 46, from Pontllanfraith, Caerphilly county, who has been with his dentist in Newbridge for more than 30 years, said: "I have been coming here since I was a child. "It's nice to see the same person on a regular basis." Mr Pegler, who has cerebral palsy and uses a wheelchair, said his family members needing to visit different surgeries could be problematic. "My wife, my child and myself could potentially be attending different practices," he said. "It's difficult to get out and to go anywhere really and if we have to go to different practices it would be impossible. "This dentist's in particular have made a big effort to make sure the practice is wheelchair accessible for me - that means a lot." Jody's dentist is Dr Harj Singhrao, owner of Newbridge Dental Care, who believes the potential breakdown in continued care will be "devastating". "If families can't be seen at the same practice, if people are punished then to join a waiting list because they have looked after their mouth, then where are they going to go? Because we know hospital waiting lists don't work," he said. The proposals are now part of a public consultation, open until 19 June, and in Cardiff people gave a mixed response to the plans when asked by BBC Wales. Robyn Weldon, 21, said: "I've been going to my dentist since I was probably six so I guess that would be a bit sad if I can't go to him. "I would say too that things haven't been going very well for the NHS so maybe this could be a good start to kind of make things easier for them and for us." Paul McCarthy, 77, said he was unaware of the changes. "I wouldn't be very happy about it either," he said. "I've been coming here for over 30 years and I'm used to coming here so I wouldn't like that at all." Justin Rees, 52, from Barry, Vale of Glamorgan, thought the new portal idea could be positive. "It's good because one, there are no appointments at the moment. "Two, it'll remind people that they need to have their teeth checked because you're busy all day and there's things that you let go," he said. In relation to how people currently access services, the consultation document says "contrary to popular belief" patients are not actually registered with a practice once their treatment ends, adding "for those who clinically require regular access, or an urgent need arises, nothing really changes". On check-ups, it says there is "false narrative" that six-monthly check-ups are necessary for everyone and that by giving people with healthy teeth a check-up less often, it will open up access for others. NICE guidelines say intervals between check-ups "should be determined specifically for each patient" and the longest interval for adults should be 18-24 months. But Dr Lauren Harrhy from the BDA said she was concerned that people may end up waiting much longer, with "most people" benefiting from regular checks. Dr Harrhy, who runs a practice in Pontypool, Torfaen, said: "If we are always having patients into the practice who need lots of work done and they are not able to be put back into the central database, there is a saturation point and at which point, access into dental practices will cease. "Our main concerns are we will have an overall reduction in the continuity of care... and we may find that dentists leave NHS dentistry which has been a trend over recent years anyway." Dentists also say the proposals offer no extra money to fund the changes. But Miles said investment in dentistry had increased year on year. "This isn't a contract we have drawn up from thin air, it is based on years worth of work, it's 13 months of negotiations with the BDA itself," he said. "No contract gives everybody exactly what they want but I am absolutely confident that for everybody - for patients, for dentists, for the NHS, for the government - this is a step forward." British Dental Association Why can't I find an NHS dentist in Wales? Fees will see more people pull teeth out - dentist Patient, 73, has 100-mile round trip for dentist
Medscape
8 hours ago
- Medscape
ASCO 2025: Key Highlights in Prostate Cancer
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from abiraterone. He also discusses positive results from the AMPLITUDE trial, where adding niraparib to standard therapy improved radiographic progression-free survival, especially in patients with BRCA1 or BRCA2 mutations, reinforcing the need for comprehensive genomic testing. Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice-changing data are still forthcoming. He emphasizes the importance of leveraging technology and community collaboration to drive progress and improve outcomes in cancer care.
Yahoo
10 hours ago
- Yahoo
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
